Roche says enicepatide cut HbA1c by 2.65 points and weight by 15.5% in a phase 2 diabetes trial, but placebo data were not released. Here is what the results show.
Source link
Roche's Enicepatide Cut Blood Sugar and Weight in Type 2 Diabetes Trial, but Placebo Figures Were Not Released
- Advertisement -